Cellular Biomedicine Group (CBMG) operates facilities in China and complies with FDA and international standards partnering with U.S., European and Asian cell therapy companies. The life sciences sector is heating up on Wall Street with innovation and deals. Cellular Biomedicine recently acquired Immune Cell Therapy Technology and its U.S. patents for $3.28 million. At the same time, the company discontinued the consulting segment of their business. Cao spoke to TheStreet's Susannah Lee on the company's expansion plans and how stem cell research works for a China based company.
Stocks in this video: